Prospective, single-centre evaluation of the safety and efficacy of percutaneous coronary interventions following a decision tree proposing a no-stent strategy in stable patients with coronary artery disease (SCRAP study).
Angioplasty
Coronary artery disease
Drug-coated balloon
Drug-eluting stent
Patient outcome assessment
Percutaneous coronary intervention
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
07
04
2022
accepted:
13
06
2022
medline:
25
8
2023
pubmed:
2
7
2022
entrez:
1
7
2022
Statut:
ppublish
Résumé
We evaluated a decision algorithm for percutaneous coronary interventions (PCI) based on a no-stent strategy, corresponding to a combination of scoring balloon angioplasty (SCBA) and drug-coated balloon (DCB), as a first line approach. Stents were used only in unstable patients, or in case of mandatory bailout stenting (BO-stent). From April 2019 to March 2020, 984 consecutive patients, including 1922 lesions, underwent PCI. The 12-month primary end-point was a composite of major adverse cardiac events (MACE) defined as all-cause death, nonfatal myocardial infarction, nonfatal stroke, and target lesion revascularization. Patients were classified into conventional or no-stent strategy groups according to the PCI strategy. In the no-stent strategy group, they were further classified into BO-stent or DCB-only groups. Their metal index was calculated by stent length divided by the total lesion length. The no-stent strategy was applied in 85% of the patients, and it was successful for 65% of them. MACE occurred in 7.1% of the study population, including 4.2% of all-cause death. Target lesion revascularization was required in 1.4%, 3.6%, and 1.5% of patients in the conventional DES, BO-stent, and DCB-only groups, respectively. MACE occurred more often in the elderly and in those treated with at least one stent (metal index greater than 0). The no-stent strategy, i.e., revascularization of coronary lesions by SCBA followed by DCB and with DES bailout stenting, was effective and safe at 1 year. This PCI approach was applicable on a daily practice in our cath lab. This study was registered with clinicaltrials.gov (NCT03893396, first posted on March 28, 2019). Feasibility, safety and efficacy of percutaneous coronary interventions following a decision tree proposing a no-stent strategy in stable patients with coronary artery disease. DES: drug eluting stent; SCBA: scoring balloon angioplasty; BO-stent: at least one stent; DCB: drug coated balloon; BMS: bare metal stent; Bailout (dash lines); MACE: major adverse cardiac event.
Identifiants
pubmed: 35776144
doi: 10.1007/s00392-022-02054-7
pii: 10.1007/s00392-022-02054-7
pmc: PMC10449686
doi:
Banques de données
ClinicalTrials.gov
['NCT03893396']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1164-1174Subventions
Organisme : Groupe Hospitalier de la Rochelle Ré Aunis
ID : 2018P02283
Organisme : B Braun Paris (FR)
ID : L-FR-2019-0184/MEDAG-19-00166
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s).
Références
JAMA Netw Open. 2020 Aug 3;3(8):e2012546
pubmed: 32756926
J Interv Cardiol. 2017 Apr;30(2):139-146
pubmed: 28116778
Am J Cardiol. 1991 Aug 15;68(5):467-71
pubmed: 1872273
JACC Cardiovasc Interv. 2022 Apr 11;15(7):770-779
pubmed: 35305906
Lancet. 2018 Sep 8;392(10150):849-856
pubmed: 30170854
J Am Coll Cardiol. 2020 Mar 10;75(9):1017-1028
pubmed: 32138961
JACC Cardiovasc Interv. 2020 Jun 22;13(12):1391-1402
pubmed: 32473887
JACC Cardiovasc Interv. 2019 Aug 12;12(15):1465-1478
pubmed: 31395217
Lancet. 2019 Jul 20;394(10194):230-239
pubmed: 31204115
Lancet. 2020 Nov 7;396(10261):1504-1510
pubmed: 33091360
Adv Ther. 2020 May;37(5):2210-2223
pubmed: 32274746
Lancet. 1978 Feb 4;1(8058):263
pubmed: 74678
Circulation. 2007 Aug 21;116(8):961-8
pubmed: 17709651
Clin Res Cardiol. 2022 Jul;111(7):732-741
pubmed: 34313800
Circ Cardiovasc Interv. 2019 Oct;12(10):e008434
pubmed: 31553205
J Am Coll Cardiol. 2017 Feb 14;69(6):616-624
pubmed: 28183505
Catheter Cardiovasc Interv. 2017 Nov 15;90(6):890-897
pubmed: 28544186
Am J Cardiol. 2016 Oct 15;118(8):1178-1186
pubmed: 27569387
Catheter Cardiovasc Interv. 2019 Feb 1;93(2):181-188
pubmed: 30280482
EuroIntervention. 2020 Apr 17;15(17):1527-1533
pubmed: 31659986
Heart Views. 2019 Jul-Sep;20(3):101-108
pubmed: 31620255
EuroIntervention. 2022 Mar 18;17(16):1330-1339
pubmed: 34881696
Circulation. 2020 Aug 11;142(6):538-545
pubmed: 32551860
Cardiovasc Interv Ther. 2019 Oct;34(4):317-324
pubmed: 30652250
Cardiol J. 2021;28(1):136-149
pubmed: 31565793
Eur Heart J. 2014 Oct 1;35(37):2541-619
pubmed: 25173339
Eur Heart J Suppl. 2021 Oct 08;23(Suppl E):E63-E67
pubmed: 34650357
J Mech Behav Biomed Mater. 2020 Sep;109:103836
pubmed: 32543402
EuroIntervention. 2021 Mar 19;16(16):1307-1317
pubmed: 33074152